Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)

Follow up study found superior progression free survival at 10 years for two cycles of escalated BEACOPP and two cycles of ABVD vs four cycles of ABVD (91.2% vs 85.6%, p<0.05), though the overall survival was not different (94.1% for both).

Source:

The Lancet Haematology